Versuchen GOLD - Frei

TCS, Infy hop onto Adobe's platform to sell AI services

Mint Chennai

|

March 25, 2025

Indian IT firms leverage the software maker's agentic AI to sell a full suite of automation tools

- Shouvik Das

TCS, Infy hop onto Adobe's platform to sell AI services

India's top software services firms, which have lagged Accenture PLC in selling generative artificial intelligence (AI)-based services to clients, are piggybacking on software maker Adobe Inc.'s platform to win more clients incorporating AI into their businesses.

Tata Consultancy Services Ltd and Infosys Ltd, the two largest technology outsourcing companies in India, are leveraging Adobe's agentic AI push to sell a full suite of automation tools, according to executives and analysts Mint spoke with. At stake is TCS and Infosys' ability to report higher revenue earned from core generative AI deals—which has been a rarity for Indian information technology (IT) services providers.

Adobe, whose key offering in its 43-year history has been its creative software platforms such as Photoshop, After Effects, InDesign and Premiere Pro, earned $21.51 billion in annual revenue last fiscal and has guided for $23.55 billion at a 9.5% annual growth in FY25. While not counted among the Big Tech companies of the US, Adobe ranks among the world's top 100 most valuable firms, with a market capitalization of $169 billion at the time of writing.

WEITERE GESCHICHTEN VON Mint Chennai

Mint Chennai

Mint Chennai

Lenskart wants artificial intelligence to test your eyes

It expects AI-enabled eye testing to become the default foundational layer of eyecare delivery

time to read

3 mins

January 13, 2026

Mint Chennai

Mint Chennai

More companies to take a hit as labour codes debut

Reworked gratuity and leave encashments spell additional expenses for India Inc

time to read

2 mins

January 13, 2026

Mint Chennai

HC lifts ban on Zydus cancer biosimilar till patent expiry

In a relief for Zydus Lifesciences, a division bench of the Delhi High Court on Monday allowed the drugmaker to sell and market its biosimilar of the anticancer drug nivolumab in India, citing public interest.

time to read

2 mins

January 13, 2026

Mint Chennai

Trump’s investigation of Powell is also a warning to the next Fed chair

The criminal investigation into Federal Reserve Chair Jerome Powell isn’t ultimately about the Fed’s headquarters, or Powell, or even interest rates.

time to read

3 mins

January 13, 2026

Mint Chennai

Mint Chennai

States flag Almont-Kid syrup as tests find contaminants

Syrup found ‘Not of Standard Quality’ with contaminants like toxic ethylene glycol

time to read

1 mins

January 13, 2026

Mint Chennai

Mint Chennai

India at 100: Our choices today will define the next two decades

India's 2047 ambition is not guaranteed but achievable if we address all the potential pitfalls along our development path

time to read

4 mins

January 13, 2026

Mint Chennai

Now, inheritance works without probate—but why it still matters

Heirs can now act on a valid will without court cases, easing delays and unlocking assets in undisputed cases

time to read

6 mins

January 13, 2026

Mint Chennai

Why VCs have a new deep-tech playbook

where fundraising starts to drag,\" said Chand.

time to read

1 min

January 13, 2026

Mint Chennai

TCS, HCLTech deliver Q3 revenue surprise

clearer.

time to read

2 mins

January 13, 2026

Mint Chennai

Mint Chennai

US productivity is rising and it risks warping monetary policy

America's neutral rate ought to be going up but will the Fed listen?

time to read

3 mins

January 13, 2026

Listen

Translate

Share

-
+

Change font size